Drug Trial Radar · NCT03636503
Rituximab + Immunotherapy in Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Oct 30, 2018
Primary completion
Jul 23, 2021
Study completion Jul 30, 2023
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Aug 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600
Conditions
- Follicular Lymphoma
Interventions
RituximabDrug
Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment
UtomilumabDrug
Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
AvelumabDrug
Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
PF04518600Drug
In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 DosingTime frame: 6 months total, assessed after each 28-day cycle
- Number of Participants With Complete Response Per Lugano CriteriaTime frame: Response assessed after completing treatment (6 months)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
City of Hope
Duarte, California
Yale New-Haven Hospital
New Haven, Connecticut
Emory University
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Washington University in St. Louis
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.